Abbott Laboratories (ABT) News
Track canonical SquawkNews coverage tagged to ABT, Abbott Laboratories. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 43 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Abbott Partners With Google Health To Combine Glucose Insights From Abbott's Lingo Biowearable With Google's Expertise In AI To Make Persona
The collaboration is designed to bring metabolic health insights into people's daily routines through a seamless, AI-powered experience. Through the Google Health app, Lingo users will be able to view glucose trends alon
EQUITY | Aug 11, 2026, 01:09 PM UTC
M
Abbott and Google Launch Partnership
Abbott partners with Google for health insights
EQUITY | Aug 11, 2026, 01:01 PM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Optio
FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment Link To P
REGULATION | Jul 27, 2026, 01:04 PM UTC
H
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth
EQUITY | Jul 27, 2026, 01:02 PM UTC
L
Freenome, Abbott announce FDA approval of SimpleScreen CRC
Freenome (FRNM) and...
EQUITY | Jul 27, 2026, 12:12 PM UTC
L
ABT Abbott Laboratories wins dismissal of shareholder lawsuit stemming from 2022 infant Formula recall, court ruling shows
ABT Abbott Laboratories wins dismissal of shareholder lawsuit stemming from 2022 infant Formula recall, court ruling shows
REGULATION | Jul 24, 2026, 07:59 PM UTC
L
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
EQUITY | Jul 21, 2026, 12:24 PM UTC
L
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - F +2.55%, EBAY +2.51%, CMG +2.32%, ULTA +1.82%, ROST +1.59% C
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - F +2.55%, EBAY +2.51%, CMG +2.32%, ULTA +1.82%, ROST +1.59% Consumer Staples (XLP) - CASY +4.30%, ADM +3.55%, BG +3.38%, MO +2.46%, PM +1.84%
RATES | Jul 17, 2026, 07:07 PM UTC
H
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results
Abbott Laboratories (NYSE: ABT ) reported upbeat second-quarter results and raised its full-year adjusted earnings outlook on Thursday. Adjusted earnings came in at $1.31 per share, topping the analyst consensus estimate
EARNINGS | Jul 17, 2026, 01:38 PM UTC
H
ABT Abbott Labs got a round of price target increases after reporting a much improved quarter on Thursday. Management also raised its full-y
ABT Abbott Labs got a round of price target increases after reporting a much improved quarter on Thursday. Management also raised its full-year guidance for adjusted earnings, forecasting a range of $5.45 to $5.60 per sh
EARNINGS | Jul 17, 2026, 01:17 PM UTC
H
Why Is Intuitive Surgical Stock Sinking Friday?
Intuitive Surgical Inc. (NASDAQ: ISRG ) stock fell more than 11% in Friday premarket trading after the robotic surgery company reported second-quarter results that topped Wall Street estimates but reaffirmed its procedur
EARNINGS | Jul 17, 2026, 11:41 AM UTC
L
ABT Raise PT to $112 from $108 after a very good Q2 and raise @ Citi
ABT Raise PT to $112 from $108 after a very good Q2 and raise @ Citi
EQUITY | Jul 17, 2026, 10:59 AM UTC
H
What You Missed On Wall Street On Thursday
The major averages closed broadly lower amid a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Earnings season has started off strong this week, as more than 87% of the 40 S&P 500
RATES | Jul 16, 2026, 08:25 PM UTC
H
Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook
Abbott Laboratories (NYSE: ABT ) stock rose Thursday after the healthcare company reported second-quarter 2026 results that beat Wall Street estimates on both earnings and revenue and raised its full-year adjusted earnin
EARNINGS | Jul 16, 2026, 05:10 PM UTC
H
Midday Fly By: UnitedHealth, United Airlines, GE Aersopace report Q2 beats
The Dow Jones Industrial Average was higher near noon while the S&P 500 and Nasdaq were lower as investors digest a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Markets continue
MACRO | Jul 16, 2026, 04:10 PM UTC
H
Abbott Stock's Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
Nothing in Abbott Laboratories (NYSE: ABT ) ‘s trading history since 1968 resembles Thursday morning. A three-cent earnings beat and a narrow guidance raise unlocked the largest single-day advance the stock has ever reco
EARNINGS | Jul 16, 2026, 02:45 PM UTC
H
Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript
Abbott Laboratories (NYSE: ABT ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and finan
EARNINGS | Jul 16, 2026, 02:27 PM UTC
H
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Nasdaq Composite falling around 150 points on Thursday. Shares of Abbott Laboratories (NYSE: ABT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 16, 2026, 02:11 PM UTC
L
Unusually active option classes on open July 16th
Unusually active option classes on open July 16th
EQUITY | Jul 16, 2026, 01:42 PM UTC
L
ABT Abbott Labs climbs to session-high 11%, up most since 2020 (more)
ABT Abbott Labs climbs to session-high 11%, up most since 2020 (more)
EQUITY | Jul 16, 2026, 01:40 PM UTC
H
ABT shares up over 10% following its earnings and guidance
ABT shares up over 10% following its earnings and guidance
EARNINGS | Jul 16, 2026, 01:35 PM UTC
L
ABT premarket highs +6% after results
ABT premarket highs +6% after results
EQUITY | Jul 16, 2026, 01:15 PM UTC
H
among early movers from the earnings calendar this morning gainers MAN +9.6%, UNH +5.9%, ABT +2.2%, STT +1.8%, CFG +1.1%, PLD +1.0% decliner
among early movers from the earnings calendar this morning gainers MAN +9.6%, UNH +5.9%, ABT +2.2%, STT +1.8%, CFG +1.1%, PLD +1.0% decliners IIIN -3.5%, GE -3.0%, USB -0.9% among early movers from the earnings calendar
EARNINGS | Jul 16, 2026, 11:57 AM UTC
L
ABT +3% premarket after 2026 profit forecast raise
ABT +3% premarket after 2026 profit forecast raise
EARNINGS | Jul 16, 2026, 11:40 AM UTC
L
Abbott sees Q3 adjusted EPS $1.38-$1.46, consensus $1.42
Abbott sees Q3 adjusted EPS $1.38-$1.46, consensus $1.42
EQUITY | Jul 16, 2026, 11:34 AM UTC
L
Abbott raises FY26 adjusted EPS view to $5.45-$5.60 from $5.38-$5.58
FY26 consensus $5.48....
EQUITY | Jul 16, 2026, 11:33 AM UTC
L
Abbott reports Q2 adjusted EPS $1.31, consensus $1.28
Reports Q2 revenue...
EARNINGS | Jul 16, 2026, 11:32 AM UTC
H
Abbott Laboratories Raises FY2026 Adj EPS Guidance from $5.38-$5.58 to $5.45-$5.60 vs $5.49 Est
Abbott Laboratories (NYSE: ABT ) raises FY2026 Adj EPS guidance from $5.38-$5.58 to $5.45-$5.60 vs $5.49 analyst estimate..
EARNINGS | Jul 16, 2026, 11:31 AM UTC
H
ABT Abbott RESULTS: Q2, Q2 ADJ EPS $1.31 vs EST $1.28, Q2 sales $12.6B vs EST $12.50B, Abbott Earnings Notes:, Outlook FY sales growth 6.5%
ABT Abbott RESULTS: Q2, Q2 ADJ EPS $1.31 vs EST $1.28, Q2 sales $12.6B vs EST $12.50B, Abbott Earnings Notes:, Outlook FY sales growth 6.5% to 7.5%, Outlook FY ADJ EPS $5.45 to $5.60 vs EST $5.49, Abbott Laboratories (AB
RATES | Jul 16, 2026, 11:30 AM UTC
H
Earnings Calendar: • Earnings Before the Open: ABT CBSH CFG GE IIIN MAN PLD STT UNH USB WIT • Earnings After the Close: AA FNB INDB ISRG NFL
Earnings Calendar: • Earnings Before the Open: ABT CBSH CFG GE IIIN MAN PLD STT UNH USB WIT • Earnings After the Close: AA FNB INDB ISRG NFLX SFNC
EARNINGS | Jul 16, 2026, 11:03 AM UTC
H
Dow Jumps 150 Points Following Producer Inflation Data: Investor Sentiment Improves, Fear & Greed Index In ‘Neutral’ Zone
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the “Neutral” zone on Wednesday. U.S. stocks settled higher on Wednesday, with the Dow Jones index g
MACRO | Jul 16, 2026, 07:17 AM UTC
H
Netflix's Q3 Earnings Report Could Lead to $21.5 Billion Swing in Market Value
Earnings are in focus on Thursday, with a -selected slate that runs from industrial engines and logistics real estate to streaming and medical devices. With guidance and segment commentary often moving stocks as much as
EARNINGS | Jul 15, 2026, 07:31 PM UTC
L
Implied EPS movers for tomorrow AM: TSM +/-4.1%, UNH +/-5.1%, GE +/-4.3%, ABT +/-4.3%, PLD +/-2.7%, USB +/-2.8%, STT +/-3.5%, CFG +/-3.9%, C
Implied EPS movers for tomorrow AM: TSM +/-4.1%, UNH +/-5.1%, GE +/-4.3%, ABT +/-4.3%, PLD +/-2.7%, USB +/-2.8%, STT +/-3.5%, CFG +/-3.9%, CBSH +/-5.7%, MAN +/-7.8%, IIIN +/-7.5%
EARNINGS | Jul 15, 2026, 06:17 PM UTC
L
FDA Approves Abbott HIV Combo Next Assay Under 510(k) BK261345 On June 29, 2026
FDA Approves Abbott HIV Combo Next Assay Under 510(k) BK261345 On June 29, 2026
REGULATION | Jul 01, 2026, 05:28 PM UTC
L
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Dav
EQUITY | Jul 01, 2026, 11:02 AM UTC
L
Baird Initiates Coverage On Abbott Laboratories with Outperform Rating, Announces Price Target of $121
Baird analyst David Rescott initiates coverage on Abbott Laboratories (NYSE: ABT ) with a Outperform rating and announces Price Target of $121.
EQUITY | Jul 01, 2026, 08:35 AM UTC
M
'The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case' - WSJ
DOJ drops baby formula probe case.
EQUITY | Jun 29, 2026, 06:54 AM UTC
M
ABT Licenses Alzheimer's Diagnostic
Abbott signs licensing agreement with ALZpath for its proprietary phosphorylated tau 217 antibody
EQUITY | Jun 24, 2026, 12:42 PM UTC
M
ABT Licenses ALZpath Tech
Abbott signs global licensing agreement with ALZpath to advance blood-based Alzheimer's disease testing
EQUITY | Jun 24, 2026, 12:32 PM UTC
L
Insiders Buy ABT, FISV, SAGT
Insiders purchase shares of ABT, FISV, SAGT, and others in recent transactions
EQUITY | Jun 22, 2026, 09:28 AM UTC
L
Insiders Buy ABT, FISV, SAGT
Insiders purchase shares of ABT, FISV, SAGT, and others in recent transactions
EQUITY | Jun 21, 2026, 04:48 PM UTC
L
ABT: Stratton Sells
Abbott Laboratories director Stratton John G P sells 2,000 shares at $86.82
EQUITY | Jun 18, 2026, 09:09 PM UTC